The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...
The FDA approved a new once-daily Parkinson’s pill in the dopamine agonist class, designed to selectively target receptors ...
AbbVie (NYSE:ABBV) today announced the launch of PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with ...
US cardiovascular biotech Cytokinetics has presented full results from ACACIA-HCM, the pivotal Phase III trial of Myqorzo (aficamten) in symptomatic non-obstructive HCM (nHCM), in the Hot Line 1 ...
Pharma and Biotechnology Events and Conferences US cardiovascular biotech Cytokinetics has presented full results from ACACIA-HCM, the pivotal Phase III trial of Myqorzo (aficamten) in symptomatic non ...
Posljednjih nekoliko godina došlo je do znatnog pomaka u liječenju Parkinsonove bolesti, a jedan od novih načina liječenja je primjena Produodopa pumpe, inovativnog uređaja koji osigurava kontinuirano ...
Schlafstörungen und Demenzrisiko – Neue Zusammenhänge 09.01.2025 - Eine neue Langzeitstudie zeigt, dass Schlafstörungen wie kurze Schlafdauer und Früherwachen das Risiko einer Demenz über Jahrzehnte ...
News und Infos zu Krankheiten, Medikamenten, Studien und Leitlinien in der Neurologie.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results